The next-generation Watchman FLX left atrial appendage occlusion device has received US Food and Drug Administration approval, device maker Boston Scientific announced Tuesday. “We will initiate a ...

SAN FRANCISCO, CA—The redesigned Watchman FLX device (Boston Scientific) provides safer left atrial appendage occlusion (LAAO) in patients with atrial fibrillation compared with the first-generation ...

Add Yahoo as a preferred source to see more of our stories on Google. Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro ...

The newer-generation Watchman device was associated with sustained safety and efficacy out to 2 years when implanted in people at high thromboembolic risk, the PINNACLE FLX IDE study group reported.

Boston Scientific (BSX) announced an update on their ongoing clinical study. Study Overview: The WATCHMAN FLX Pro European Registry, officially titled the same, is a clinical study initiated by Boston ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...

In-hospital safety and procedural outcomes for percutaneous left atrial appendage (LAA) closure are substantially better with the Watchman FLX device than with its predecessor, new research shows.

Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...